10-Q

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2010

or

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                      to                     

Commission file number: 000-32883

WRIGHT MEDICAL GROUP, INC.

(Exact Name of Registrant as Specified in Its Charter)

Delaware (State or Other Jurisdiction of Incorporation or Organization)	13-4088127 (IRS Employer Identification Number)
5677 Airline Road Arlington, Tennessee (Address of Principal Executive Offices)	38002 (Zip Code)

(901) 867-9971
(Registrant’s Telephone Number, Including Area Code)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.       þ Yes o No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files.)      þ Yes o No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer þ	Accelerated filer o	Non-accelerated filer o	Smaller Reporting Company o
		(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).      o Yes þ No

As of October 25, 2010, there were 39,190,314 shares of common stock outstanding.

WRIGHT MEDICAL GROUP, INC.

TABLE OF CONTENTS

	Page Number
PART I — FINANCIAL INFORMATION
Item 1. Financial Statements (unaudited).		1
Condensed Consolidated Balance Sheets as of September 30, 2010 and December 31, 2009		1
Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2010 and 2009		2
Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2010 and 2009		3
Notes to Condensed Consolidated Financial Statements		4
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.		13
Item 3. Quantitative and Qualitative Disclosures About Market Risk.		23
Item 4. Controls and Procedures.		24
PART II — OTHER INFORMATION
Item 1. Legal Proceedings.		25
Item 1A. Risk Factors.		25
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.		26
Item 3. Defaults Upon Senior Securities.		26
Item 4. [Removed and Reserved.]		26
Item 5. Other Information.		26
Item 6. Exhibits.		26
SIGNATURES		30
EX-31.1
EX-31.2
EX-32
EX-101 INSTANCE DOCUMENT
EX-101 SCHEMA DOCUMENT
EX-101 CALCULATION LINKBASE DOCUMENT
EX-101 LABELS LINKBASE DOCUMENT
EX-101 PRESENTATION LINKBASE DOCUMENT
EX-101 DEFINITION LINKBASE DOCUMENT

SAFE-HARBOR STATEMENT

This quarterly report contains “forward-looking statements” as defined under U.S. federal securities laws. These statements reflect management’s current knowledge, assumptions, beliefs, estimates, and expectations and express management’s current views of future performance, results, and trends and may be identified by their use of terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “will,” and other similar terms. Forward-looking statements are subject to a number of risks and uncertainties that could cause our actual results to materially differ from those described in the forward-looking statements. Readers should not place undue reliance on forward-looking statements. Such statements are made as of the date of this quarterly report, and we undertake no obligation to update such statements after this date.

Risks and uncertainties that could cause our actual results to materially differ from those described in forward-looking statements include those discussed in our filings with the Securities and Exchange Commission (including those described in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2009, under the heading, “Risk Factors” and in Item 1A of Part II and elsewhere in this report), and the following:

• the impact of our settlement of the federal investigation into our consulting arrangements with orthopaedic surgeons relating to our hip and knee products in the United States, including our compliance with the Deferred Prosecution Agreement through September 2011 and the Corporate Integrity Agreement through September 2015;

• demand for and market acceptance of our new and existing products;

• recently enacted healthcare reform legislation and its future implementation, possible additional legislation, regulation and other governmental pressures in the United States or globally, which may affect pricing, reimbursement, taxation and rebate policies of government agencies and private payers or other elements of our business;

• tax reform measures, tax authority examinations and associated tax risks and potential obligations;

• our ability to identify business development and growth opportunities for existing or future products;

• product quality or patient safety issues, leading to product recalls, withdrawals, launch delays, sanctions, seizures, litigation, or declining sales;

• individual, group or class action alleging products liability claims, including an increase in the number of claims during any period;

• future actions of the FDA or any other regulatory body or government authority that could delay, limit or suspend product development, manufacturing or sale or result in seizures, injunctions, monetary sanctions or criminal or civil liabilities;

• our ability to enforce our patent rights or patents of third parties preventing or restricting the manufacture, sale or use of affected products or technology;

• the impact of geographic and product mix on our sales;

• retention of our sales representatives and independent distributors;

• inventory reductions or fluctuations in buying patterns by wholesalers or distributors;

• our ability to realize the anticipated benefits of restructuring initiatives; and

• any impact of the commercial and credit environment on us and our customers and suppliers.

PART I — FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS (unaudited).

WRIGHT MEDICAL GROUP, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except share data)
(unaudited)

	September 30,		December 31,
	2010		2009
Assets:
Current assets:
Cash and cash equivalents	$	123,170	$	84,409
Marketable securities		33,512		86,819
Accounts receivable, net		98,415		101,720
Inventories		167,058		163,535
Prepaid expenses		10,924		13,122
Deferred income taxes		35,008		34,824
Other current assets		5,204		6,175
Total current assets		473,291		490,604
Property, plant and equipment, net		151,860		139,708
Goodwill		53,716		53,860
Intangible assets, net		16,735		17,727
Marketable securities		34,124		—
Deferred income taxes		6,169		5,248
Other assets		7,792		7,137
Total assets	$	743,687	$	714,284
Liabilities and Stockholders’ Equity:
Current liabilities:
Accounts payable	$	16,872	$	13,978
Accrued expenses and other current liabilities		61,841		54,643
Current portion of long-term obligations		305		336
Total current liabilities		79,018		68,957
Long-term debt and capital lease obligations		200,301		200,326
Deferred income taxes		153		157
Other liabilities		4,782		4,436
Total liabilities	$	284,254	$	273,876
Commitments and contingencies (Note 10)
Stockholders’ equity:
Common stock, $.01 par value, authorized: 100,000,000 shares; issued and outstanding: 39,189,950 shares at September 30, 2010 and 38,668,882 shares at December 31, 2009		379		374
Additional paid-in capital		387,009		376,647
Accumulated other comprehensive income		22,592		22,906
Retained earnings		49,453		40,481
Total stockholders’ equity		459,433		440,408
Total liabilities and stockholders’ equity	$	743,687	$	714,284

The accompanying notes are an integral part of these condensed consolidated financial statements.

1

WRIGHT MEDICAL GROUP, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share data)
(unaudited)

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2010		2009		2010		2009
Net sales	$	121,708	$	117,742	$	380,686	$	357,580
Cost of sales 1		37,989		35,880		118,064		110,646
Gross profit		83,719		81,862		262,622		246,934
Operating expenses:
Selling, general and administrative 1		64,877		63,703		209,089		196,133
Research and development 1		8,779		8,537		28,398		26,460
Amortization of intangible assets		708		1,274		1,991		3,899
Restructuring charges (Note 9)		134		131		1,139		991
Total operating expenses		74,498		73,645		240,617		227,483
Operating income		9,221		8,217		22,005		19,451
Interest expense, net		1,532		1,435		4,550		3,974
Other expense (income), net		313		108		270		(358	)
Income before income taxes		7,376		6,674		17,185		15,835
Provision for income taxes		2,726		2,522		8,213		5,939
Net income	$	4,650	$	4,152	$	8,972	$	9,896
Net income per share (Note 7):
Basic	$	0.12	$	0.11	$	0.24	$	0.27
Diluted	$	0.12	$	0.11	$	0.24	$	0.26
Weighted-average number of shares outstanding-basic		37,935		37,431		37,748		37,331
Weighted-average number of shares outstanding-diluted		38,011		37,551		37,923		37,395

¹ These line items include the following amounts of non-cash, stock-based compensation expense for the periods indicated:

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2010		2009		2010		2009
Cost of sales	$	314	$	335	$	980	$	938
Selling, general and administrative		2,261		2,517		7,700		7,822
Research and development		492		480		1,500		1,440

The accompanying notes are an integral part of these condensed consolidated financial statements.

2

WRIGHT MEDICAL GROUP, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
(unaudited)

	Nine Months Ended
	September 30,
	2010			2009
Operating activities:
Net income	$	8,972		$	9,896
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation		26,073			23,865
Stock-based compensation expense		10,180			10,200
Amortization of intangible assets		1,991			3,899
Amortization of deferred financing costs		777			738
Deferred income taxes		(3,470	)		(2,709	)
Excess tax benefit from stock-based compensation arrangements		(288	)		(24	)
Non-cash restructuring charges		246			—
Other		1,170			(14	)
Changes in assets and liabilities (net of acquisitions):
Accounts receivable		3,384			(5,925	)
Inventories		(2,736	)		10,418
Prepaid expenses and other current assets		2,527			8,200
Accounts payable		2,949			(1,968	)
Accrued expenses and other liabilities		8,221			(6,465	)
Net cash provided by operating activities		59,996			50,111
Investing activities:
Capital expenditures		(35,950	)		(26,360	)
Acquisitions of businesses		(2,072	)		(5,973	)
Purchase of intangible assets		(1,598	)		(882	)
Investment in held-to-maturity marketable securities		(4,674	)		—
Sales and maturities of available-for-sale marketable securities		104,049			65,192
Investment in available-for-sale marketable securities		(81,067	)		(48,324	)
Net cash used in investing activities		(21,312	)		(16,347	)
Financing activities:
Issuance of common stock		461			231
Principal payments of bank and other financing		(968	)		(107	)
Financing under factoring agreements, net		5			(58	)
Excess tax benefit from stock-based compensation arrangements		288			24
Net cash (used in) provided by financing activities		(214	)		90
Effect of exchange rates on cash and cash equivalents		291			(485	)
Net increase in cash and cash equivalents		38,761			33,369
Cash and cash equivalents, beginning of period		84,409			87,865
Cash and cash equivalents, end of period	$	123,170		$	121,234

The accompanying notes are an integral part of these condensed consolidated financial statements.

3

WRIGHT MEDICAL GROUP, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

1. Summary of Significant Accounting Policies

Basis of Presentation. The unaudited condensed consolidated interim financial statements of Wright Medical Group, Inc. have been prepared in accordance with accounting principles generally accepted in the United States (U.S.) for interim financial information and the instructions to Quarterly Report on Form 10-Q and Rule 10-01 of Regulation S-X. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the U.S. have been condensed or omitted pursuant to these rules and regulations. Accordingly, these unaudited condensed consolidated interim financial statements should be read in conjunction with our consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2009, as filed with the U.S. Securities and Exchange Commission (SEC).

In the opinion of management, these unaudited condensed consolidated interim financial statements reflect all adjustments necessary for a fair presentation of our interim financial results. All such adjustments are of a normal and recurring nature. The results of operations for any interim period are not indicative of results for the full fiscal year.

The accompanying unaudited condensed consolidated interim financial statements include our accounts and those of our wholly-owned domestic and international subsidiaries. Intercompany accounts and transactions have been eliminated in consolidation.

Marketable Securities. We have historically invested in treasury bills, government and agency bonds, and certificates of deposit with maturity dates of less than 12 months. Beginning in the second quarter of 2010, we also invested in marketable securities with maturity dates greater than 12 months. Our investments in these marketable securities are classified as available-for-sale securities in accordance with Financial Accounting Standards Board (FASB) Accounting Standard Codification (ASC) Topic 320, Investments — Debt and Equity Securities. These securities are carried at their fair value, and all unrealized gains and losses are recorded within other comprehensive income. In the third quarter of 2010, we invested in a bank deposit with a maturity date of 12 months. This investment, which is classified as held-to-maturity, is carried at its amortized cost. Marketable securities are classified as short-term for those expected to mature or be sold within 12 months and the remaining portion is classified as long-term. The cost of investment securities sold is determined by the specific identification method.

The following tables present a summary of our marketable securities (in thousands):

			Gross		Gross
	Amortized		Unrealized		Unrealized			Estimated
	Cost		Gains		(Losses)			Fair Value
At September 30, 2010
Available-for-sale marketable securities
Municipal debt securities	$	903	$	3	$	—		$	906
U.S. agency debt securities		41,356		28		(2	)		41,382
Certificates of deposits		1,363		—		—			1,363
Corporate debt securities		3,199		13		—			3,212
U.S. government debt securities		16,034		26		—			16,060
Total available-for-sale marketable securities	$	62,855	$	70	$	(2	)	$	62,923
Held-to-maturity time deposits	$	4,713	$	—	$	—		$	4,713
Total marketable securities	$	67,568	$	70	$	(2	)	$	67,636

			Gross		Gross
	Amortized		Unrealized		Unrealized			Estimated
	Cost		Gains		(Losses)			Fair Value
At December 31, 2009
Available-for-sale marketable securities
U.S. agency debt securities	$	69,819	$	11	$	(50	)	$	69,780
Certificates of deposits		1,435		—		(5	)		1,430
U.S. government debt securities		15,604		10		(5	)		15,609
Total available-for-sale marketable securities	$	86,858	$	21	$	(60	)	$	86,819

4

WRIGHT MEDICAL GROUP, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
(UNAUDITED)

The maturities of available-for-sale and held-to-maturity debt securities at September 30, 2010 are as follows:

	Available-for-Sale				Held-to-maturity
	Cost Basis		Fair Value		Cost Basis		Fair Value
Due in one year or less	$	28,786	$	28,799	$	4,713	$	4,713
Due after one year through two years		26,569		26,620		—		—
Due after two years		7,500		7,504		—		—
	$	62,855	$	62,923	$	4,713	$	4,713

Fair Value of Financial Instruments. The carrying values of cash and cash equivalents, accounts receivable, and accounts payable approximate the fair values of these financial instruments as of September 30, 2010 and December 31, 2009 due to their short maturities.

Effective January 1, 2008, we adopted the provisions of Statement of Financial Accounting Standards (SFAS) No. 157, Fair Value Measurements (SFAS 157), for financial assets and liabilities measured at fair value on a recurring basis. Effective January 1, 2009, we adopted the provisions of SFAS 157 for nonfinancial assets and liabilities measured at fair value on a recurring basis. SFAS 157 applies to all financial and nonfinancial assets and liabilities that are being measured and reported on a fair value basis, establishes a framework for measuring the fair value of assets and liabilities, and expands disclosures about fair value measurements. The adoption of SFAS 157 had no impact to our condensed consolidated interim financial statements. Effective July 1, 2009, this standard was incorporated into FASB ASC Topic 820, Fair Value Measurements and Disclosures (FASB ASC 820). FASB ASC 820-10-50 requires fair value measurements be classified and disclosed in one of the following three categories:

Level 1:	Financial instruments with unadjusted, quoted prices listed on active market exchanges.
Level 2:	Financial instruments determined using prices for recently traded financial instruments with similar underlying terms as well as directly or indirectly observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals.
Level 3:	Financial instruments that are not actively traded on a market exchange. This category includes situations where there is little, if any, market activity for the financial instrument. The prices are determined using significant unobservable inputs or valuation techniques.

As of September 30, 2010 and December 31, 2009, we had current marketable securities totaling $33.5 million and $86.8 million, respectively, consisting of investments in treasury bills, government and agency bonds, and certificates of deposits, all of which are valued at fair value using a market approach. In addition, we had noncurrent marketable securities totaling $34.1 million as of September 30, 2010, consisting of investments in government, agency, and corporate bonds, all of which are valued at fair value using a market approach.

The following table summarizes the valuation of our financial instruments (in thousands):

5

WRIGHT MEDICAL GROUP, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
(UNAUDITED)

					Prices with
			Quoted Prices		Other		Prices with
			in Active		Observable		Unobservable
			Markets		Inputs		Inputs
	Total		(Level 1)		(Level 2)		(Level 3)
At September 30, 2010
Assets
Cash and cash equivalents	$	123,170	$	123,170	$	—	$	—
Available-for-sale marketable securities
Municipal debt securities	$	906	$	906	$	—	$	—
U.S. agency debt securities		41,382		41,382		—		—
Certificates of deposits		1,363		—		1,363		—
Corporate debt securities		3,212		3,212		—		—
U.S. government debt securities		16,060		16,060		—		—
Total available-for-sale marketable securities		62,923		61,560		1,363		—
Held-to-maturity time deposits		4,713		—		4,713		—
	$	190,806	$	184,730	$	6,076	$	—
Liabilities
Convertible Senior Notes		178,000		178,000		—		—
	$	178,000	$	178,000	$	—	$	—

					Prices with
			Quoted Prices		Other		Prices with
			in Active		Observable		Unobservable
			Markets		Inputs		Inputs
	Total		(Level 1)		(Level 2)		(Level 3)
At December 31, 2009
Assets
Cash and cash equivalents	$	84,409	$	84,409	$	—	$	—
Available-for-sale marketable securities
U.S. agency debt securities	$	69,780	$	69,780	$	—	$	—
Certificates of deposits		1,430		—		1,430		—
U.S. government debt securities		15,609		15,609		—		—
		86,819		85,389		1,430		—
	$	171,228	$	169,798	$	1,430	$	—
Liabilities
Convertible Senior Notes		176,000		176,000		—		—
	$	176,000	$	176,000	$	—	$	—

2. Inventories

Inventories consist of the following (in thousands):

	September 30,		December 31,
	2010		2009
Raw materials	$	8,354	$	8,606
Work-in-process		25,543		23,766
Finished goods		133,161		131,163
	$	167,058	$	163,535

6

WRIGHT MEDICAL GROUP, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
(UNAUDITED)

3. Property, Plant and Equipment, Net

Property, plant and equipment consist of the following (in thousands):

	September 30,			December 31,
	2010			2009
Property, plant and equipment, at cost	$	314,741		$	286,086
Less: Accumulated depreciation		(162,881	)		(146,378	)
	$	151,860		$	139,708

4. Long-Term Debt and Capital Lease Obligations

Long-term debt and capital lease obligations consist of the following (in thousands):

	September 30,			December 31,
	2010			2009
Capital lease obligations	$	606		$	662
Convertible senior notes		200,000			200,000
		200,606			200,662
Less: current portion		(305	)		(336	)
	$	200,301		$	200,326

In November 2007, we issued $200 million of Convertible Senior Notes due 2014. The notes will mature on December 1, 2014. The notes pay interest semiannually at an annual rate of 2.625% and are convertible into shares of our common stock at an initial conversion rate of 30.6279 shares per $1,000 principal amount of the notes, which represents a conversion price of $32.65 per share. The holder of the notes may convert at any time on or prior to the close of business on the business day immediately preceding the maturity date of notes. Beginning on December 6, 2011, we may redeem the notes, in whole or in part, at a redemption price equal to 100% of the principal amount of the notes, plus accrued and unpaid interest, if the closing price of our common stock has exceeded 140% of the conversion price for at least 20 days during any consecutive 30-day trading period. Additionally, if we experience a fundamental change event, as defined in the note agreement, the holders may require us to purchase for cash all or a portion of the notes for 100% of the principal amount of the notes, plus accrued and unpaid interest. If upon a fundamental change event, a holder elects to convert its notes, we may, under certain circumstances, increase the conversion rate for the notes surrendered. The notes are unsecured obligations and are subordinate to all existing and future secured debt, our revolving credit facility, and all liabilities of our subsidiaries.

On June 30, 2010, we renewed our revolving credit facility. The revolving credit facility has availability of $100 million, which can be increased by up to an additional $50 million at our request and subject to the agreement of the lenders. We currently have no borrowings outstanding under the credit facility. Borrowings under the credit facility will bear interest at the sum of a base rate or Eurodollar rate plus an applicable margin that ranges from 0.25% to 2.50% depending on the type of loan and our consolidated leverage ratio, with a current annual base rate of 3.25% and a Eurodollar rate of 0.46% (6 month rate). The term of the credit facility extends through June 30, 2014.

5. Goodwill and Intangible Assets

Changes in the carrying amount of goodwill occurring during the nine months ended September 30, 2010, are as follows (in thousands):

Goodwill at December 31, 2009	$	53,860
Goodwill from contingent consideration associated with acquisitions prior to 2010		258
Foreign currency translation		(402	)
Goodwill at September 30, 2010	$	53,716

7

WRIGHT MEDICAL GROUP, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
(UNAUDITED)

During the nine months ended September 30, 2010, we made payments for contingent consideration of $237,000 associated with the acquisition of the assets of Creative Medical Designs, Inc. and Rayhack LLC, which was accrued as of December 31, 2009, and $1.8 million associated with the acquisition of the assets of Inbone Technologies, Inc., completed in 2008, of which $1.7 million was accrued as of December 31, 2009.

The components of our identifiable intangible assets are as follows (in thousands):

	September 30, 2010					December 31, 2009
				Accumulated					Accumulated
	Cost			Amortization		Cost			Amortization
Distribution channels	$	21,249		$	21,087	$	22,207		$	22,025
Completed technology		12,645			5,922		12,537			5,213
Licenses		8,006			4,327		7,245			3,777
Customer relationships		3,750			992		3,750			720
Trademarks		2,753			707		2,733			570
Other		2,824			1,457		2,620			1,060
		51,227		$	34,492		51,092		$	33,365
Less: Accumulated amortization		(34,492	)				(33,365	)
Intangible assets, net	$	16,735				$	17,727

Based on the intangible assets held at September 30, 2010, we expect to amortize approximately $2.7 million for the full year of 2010, $2.5 million in 2011, $2.2 million in 2012, $1.9 million in 2013, and $1.7 million in 2014.

6. Stock-Based Compensation

Amounts recognized within the condensed consolidated financial statements are as follows (in thousands):

	Three Months Ended						Nine Months Ended
	September 30,						September 30,
	2010			2009			2010			2009
Total cost of share-based payment plans	$	3,121		$	3,399		$	10,216		$	10,314
Amounts capitalized as inventory and intangible assets		(371	)		(402	)		(1,025	)		(1,052	)
Amortization of capitalized amounts		317			335			989			938
Charged against income before income taxes		3,067			3,332			10,180			10,200
Amount of related income tax benefit		(1,116	)		(968	)		(3,266	)		(3,005	)
Impact to net income	$	1,951		$	2,364		$	6,914		$	7,195
Impact to basic earnings per share	$	0.05		$	0.06		$	0.18		$	0.19
Impact to diluted earnings per share	$	0.05		$	0.06		$	0.18		$	0.19

In the nine-month period ended September 30, 2010, we granted approximately 296,000 stock options, 504,000 non-vested shares of common stock, and 88,000 restricted stock units at weighted-average fair values of $6.98, $18.35 and $18.31, respectively, which will be recognized on a straight line basis over the requisite service period of four years. Of the 296,000 stock options granted in the nine-month period ended September 30, 2010, 65,000 were granted as an inducement grant. As of September 30, 2010, we had approximately 4.0 million stock options (of which approximately 3.1 million were exercisable), 1.3 million non-vested shares of common stock, 18,000 stock-settled phantom stock units, and 119,000 restricted stock units outstanding.

As of September 30, 2010, we had $23.7 million of total unrecognized compensation cost related to unvested stock-based compensation arrangements granted to employees, which is expected to be recognized over a weighted-average period of 2.6 years.

8

WRIGHT MEDICAL GROUP, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
(UNAUDITED)

7. Earnings Per Share

FASB ASC Topic 260, Earnings Per Share, requires the presentation of basic and diluted earnings per share. Basic earnings per share is calculated based on the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per share is calculated to include any dilutive effect of our common stock equivalents. Our common stock equivalents consist of stock options, non-vested shares of common stock, stock-settled phantom stock units, restricted stock units, and convertible debt. The dilutive effect of the stock options, non-vested shares of common stock, stock-settled phantom stock units, and restricted stock units is calculated using the treasury-stock method. The dilutive effect of convertible debt is calculated by applying the “if-converted” method. This assumes an add-back of interest, net of income taxes, to net income as if the securities were converted at the beginning of the period. During the three-month and nine-month periods ending September 30, 2010 and 2009, the convertible debt had an anti-dilutive effect on earnings per share and we therefore excluded it from the dilutive shares calculation.

The weighted-average number of shares outstanding for basic and diluted earnings per share is as follows (in thousands):

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2010		2009		2010		2009
Weighted-average number of shares outstanding, basic		37,935		37,431		37,748		37,331
Common stock equivalents		76		120		175		64
Weighted-average number of shares outstanding, diluted		38,011		37,551		37,923		37,395

The following potential common shares were excluded from the computation of diluted earnings per share as their effect would have been anti-dilutive (in thousands):

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2010		2009		2010		2009
Stock options		3,943		4,120		3,856		4,118
Non-vested shares, restricted stock units, and stock-settled phantom stock units		626		530		687		1,231
Convertible debt		6,126		6,126		6,126		6,126

8. Other Comprehensive Income

The difference between our net income and our comprehensive income is attributable to foreign currency translation, unrealized gains and losses on our available-for-sale marketable securities, and adjustments related to our minimum pension liability in Japan. The following table provides a reconciliation of net income to comprehensive income (in thousands):

	Three Months Ended					Nine Months Ended
	September 30,					September 30,
	2010		2009			2010			2009
Net income	$	4,650	$	4,152		$	8,972		$	9,896
Changes in foreign currency translation		6,728		2,449			(434	)		3,251
Unrealized gain (loss) on marketable securities		16		(39	)		107			(394	)
Minimum pension liability adjustment		5		4			13			12
Comprehensive income	$	11,399	$	6,566		$	8,658		$	12,765

9

WRIGHT MEDICAL GROUP, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
(UNAUDITED)

9. Restructuring

Toulon, France

In June 2007, we announced plans to close our manufacturing, distribution, and administrative facility located in Toulon, France. The facility’s closure affected approximately 130 Toulon-based employees. The majority of our restructuring activities were complete by the end of 2007, with production now conducted in our existing manufacturing facility in Arlington, Tennessee, and European distribution activities being carried out from our European headquarters in Amsterdam, the Netherlands.

Management estimates that the pre-tax restructuring charges will total approximately $28 million to $30 million. These charges consist of the following estimates:

• $14 million for severance and other termination benefits;

• $3 million of non-cash asset impairments of property, plant and equipment;

• $2 million of inventory write-offs and manufacturing period costs;

• $3 million to $4 million of external legal and professional fees; and

• $6 million to $7 million of other cash and non-cash charges (including employee litigation).

Charges associated with the restructuring are presented in the following table. All of the following amounts were recognized within “Restructuring charges” in our consolidated statement of operations, with the exception of the inventory write-offs and manufacturing period costs, which were recognized within “Cost of sales — restructuring.”

	Three Months			Nine Months		Cumulative
	Ended			Ended		Charges as of
(in thousands)	September 30, 2010			September 30, 2010		September 30, 2010
Severance and other termination benefits	$	2		$	26	$	13,576
Employee litigation accrual		(5	)		103		5,151
Asset impairment charges		—			—		3,093
Inventory write-offs and manufacturing period costs		—			—		2,139
Legal/professional fees		137			339		3,356
Other		—			—		194
Total restructuring charges	$	134		$	468	$	27,509

Activity in the restructuring liability for the nine months ended September 30, 2010 is presented in the following table (in thousands):

Beginning balance as of December 31, 2009	$	4,964
Charges:
Severance and other termination benefits		26
Employee litigation accrual		103
Legal/professional fees		339
Total accruals		468
Payments:
Severance and other termination benefits		(16	)
Employee litigation accrual		(1,098	)
Legal/professional fees		(404	)
Total payments		(1,518	)
Changes in foreign currency translation		(358	)
Restructuring liability at September 30, 2010	$	3,556

In connection with the closure of our Toulon, France facility, 103 of our former employees have filed claims to challenge the economic justification for their dismissal. To date, judgments have been rendered for 86 of those claims, the substantial majority of which were unfavorable to us and for which we have been required to pay a portion of the judgment, totaling approximately $1.1 million. An appellate hearing related to these judgments was held during the three months ended September 30, 2010, however a ruling has not been issued. Management has

10

WRIGHT MEDICAL GROUP, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
(UNAUDITED)

estimated the remaining probable liability upon the ultimate resolution of these 103 claims to be $3.3 million, and has therefore recorded this amount as a liability within “Accrued expenses and other current liabilities” in our condensed consolidated balance sheet as of September 30, 2010.

Creteil, France

In October 2009, we announced plans to close our distribution and finance support office in Creteil, France, in order to migrate all relevant French distribution and support functions into our European organization based out of our European headquarters in Amsterdam, the Netherlands.

As of September 30, 2010, we have concluded our restructuring efforts in Creteil, incurring a total of $2.8 million of charges, however certain liabilities remain to be paid. No charges were incurred in the three months ended September 30, 2010.

Charges associated with the restructuring are presented in the following table. All of the following amounts were recognized within “Restructuring charges” in our consolidated statement of operations.

	Nine Months		Cumulative
	Ended		Charges as of
(in thousands)	September 30, 2010		September 30, 2010
Severance and other termination benefits	$	52	$	876
Asset disposals		121		121
Legal/professional fees		66		328
Contract termination costs		133		1,128
Other		299		299
Total restructuring charges	$	671	$	2,752

Activity in the restructuring liability for the nine months ended September 30, 2010 is presented in the following table (in thousands):

Beginning balance as of December 31, 2009	$	1,817
Charges:
Severance and other termination benefits		52
Contract termination costs		6
Legal/professional fees		66
Other		299
Total accruals		423
Payments:
Severance and other termination benefits		(647	)
Contract termination costs		(927	)
Legal/professional fees		(197	)
Other		(311	)
Total payments		(2,082	)
Changes in foreign currency translation		(70	)
Restructuring liability at September 30, 2010	$	88

10. Commitments and Contingencies

In December 2007, we received a subpoena from the United States Department of Justice (DOJ) through the United States Attorney’s Office for the District of New Jersey (USAO) requesting documents for the period January 1998 through the present related to any consulting and professional service agreements with orthopaedic surgeons in connection with hip or knee joint replacement procedures or products. This subpoena was served shortly after several of our knee and hip competitors agreed to resolutions with the DOJ after being subjects of investigations involving the same subject matter.

11

WRIGHT MEDICAL GROUP, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
(UNAUDITED)

On September 29, 2010, our wholly-owned subsidiary, Wright Medical Technology, Inc. (WMT) entered into a 12-month Deferred Prosecution Agreement (DPA) with the USAO and a Civil Settlement Agreement (CSA) with the United States. Under the DPA, the USAO agrees not to prosecute WMT in connection with the matter if WMT satisfies its obligations during the 12 month term of the DPA. Pursuant to the CSA, WMT settled civil and administrative claims relating to the matter for a payment of $7.9 million without any admission by WMT. In conjunction with the CSA, WMT also entered into a five year Corporate Integrity Agreement (CIA) with the Office of the Inspector General of the United States Department of Health and Human Services. Pursuant to the DPA, an independent monitor will review and evaluate WMT’s compliance with its obligations under the DPA. Together, these agreements resolve the investigation commenced by the USAO in December 2007. The USAO specifically acknowledges in the DPA that it does not allege that WMT’s conduct adversely affected patient health or patient care.

We previously accrued a provision of approximately $8 million for an anticipated settlement of this investigation; therefore, we did not have a material impact to our consolidated financial position or results of operations during the three months ended September 30, 2010 related to these settlements.

As of September 30, 2010, the trade receivable balance due from our stocking distributor in Turkey was $9.4 million, of which a significant portion is past due. We have a reserve of $5.6 million against this balance as of June 30, 2010. It is possible that the future realization of this accounts receivable balance could be more or less than the remaining unreserved balance of $3.8 million.

In addition to the stocking distributor in Turkey, our next ten largest international stocking distributors have net trade receivable balances totaling approximately $17 million as of September 30, 2010. No allowance has been provided on these balances as management believes it is probable that the balances will be fully collected. However, it is at least reasonably possible that changes in global economic conditions and/or local operating and economic conditions in the regions these distributors operate, or other factors, could affect the future realization of these accounts receivable balances.

In addition to those noted above, we are subject to various other legal proceedings, product liability claims, and other matters which arise in the ordinary course of business. In the opinion of management, the amount of liability, if any, with respect to these matters, will not materially affect our consolidated results of operations or financial position.

12

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

General

The following management’s discussion and analysis of financial condition and results of operations describes the principal factors affecting the results of our operations, financial condition, and changes in financial condition for the three- and nine-month periods ended September 30, 2010. This discussion should be read in conjunction with the accompanying unaudited financial statements, our Annual Report on Form 10-K for the year ended December 31, 2009, which includes additional information about our critical accounting policies and practices and risk factors, and Item 1A of Part II of this report, which updates those risk factors.

Executive Overview

Company Description. We are a global orthopaedic medical device company specializing in the design, manufacture, and marketing of devices and biologic products for extremity, hip, and knee repair and reconstruction. Extremity hardware includes implants and other devices to replace or reconstruct injured or diseased joints and bones of the foot, ankle, hand, wrist, elbow, and shoulder, which we generally refer to as either foot and ankle or upper extremity products. We are a leading provider of surgical solutions for the foot and ankle market. Reconstructive devices are used to replace or repair knee, hip, and other joints and bones that have deteriorated or been damaged through disease or injury. Biologics are used to repair or replace damaged or diseased bone, to stimulate bone growth and to provide other biological solutions for surgeons and their patients. Within these markets, we focus on the higher-growth sectors of the orthopaedic industry, such as the foot and ankle market, as well as on the integration of our biologic products into reconstructive procedures and other orthopaedic applications. Our extensive foot and ankle product portfolio, our over 150 specialized foot and ankle sales representatives, and our increasing level of training of foot and ankle surgeons has resulted in our being a recognized leader in the foot and ankle market. We have been in business for over 60 years and have built a well-known and respected brand name and strong relationships with orthopaedic surgeons and surgical podiatrists.

Principal Products. We primarily sell devices and biologic products for extremity, hip, and knee repair and reconstruction. We specialize in extremity and biologic products used by extremity focused surgeon specialists for the reconstruction, trauma, and arthroscopy markets. Our biologics sales encompass a broad portfolio of products designed to stimulate and augment the natural regenerative capabilities of the human body. We also sell orthopaedic products not considered to be part of our knee, hip, extremity, or biologic product lines.

Significant Quarterly Business Developments. Net sales increased 3% in the third quarter of 2010 to $121.7 million, compared to net sales of $117.7 million in the third quarter of 2009. In the third quarter of 2010, we recorded net income of $4.7 million, compared to net income of $4.2 million for the third quarter of 2009, primarily as a result of decreased expenses relating to ongoing governmental inquiries, decreased amortization expense, and decreased levels of non-cash, stock based compensation expense.

Our third quarter domestic sales increased 1% in 2010, primarily due to 13% growth within our extremity line. Our domestic extremities growth is primarily attributable to higher sales volume of our foot and ankle products, in particular our INBONE^™ products, our ORTHOLOC^™ Polyaxial Locked Plating System, launched in September 2009, our DARCO^® plating systems, and our VALOR^® Hindfoot Fusion Nail System launched in June 2010. Domestic sales of our biologic products increased by 2% in the third quarter of 2010 as compared to the same period in 2009. Our domestic knee sales and domestic hip sales decreased by 5% and 9%, respectively, in the third quarter of 2010 as compared to the same period in 2009 due to lower levels of unit sales volume as well as lower pricing, both of which are impacted by market conditions throughout the industry.

Our international sales increased 7% to $47.1 million in the third quarter of 2010, compared to $44.0 million in the third quarter of 2009. This increase in sales in the third quarter of 2010 compared to 2009 is primarily the result of increased sales in Japan, Latin America and Australia.

During the three months ended September 30, 2010, we reached a settlement agreement with the United States for a payment $7.9 million without any admission by us. In addition, pursuant to a Deferred Prosecution Agreement, an independent monitor will review and evaluate our compliance with our obligations under this agreement for a period of 12 months.

Opportunities and Challenges. Our results of operations can be substantially affected not only by global economic conditions, but also by local operating and economic conditions, which can vary substantially by market.

13

Unfavorable conditions can depress sales in a given market and may result in actions that adversely affect our margins, constrain our operating flexibility, or result in charges which are unusual or non-recurring. The global economy negatively impacted industry growth rates in both domestic and international markets beginning in 2009, and we are unable to predict when these markets will return to historical rates of growth, if ever.

In our domestic markets, we expect that an expansion of our focused foot and ankle sales force and new product offerings will continue to favorably impact our extremities and biologics businesses in the remainder of 2010. We believe that our domestic hip and knee business will be unfavorably impacted by market conditions during the remainder of the year.

During 2010, we expect positive impact from our increased presence in Australia and the annualization of the lower levels of revenues from our international stocking distributor business. Given these expectations, we anticipate moderate levels of sales growth in our international business for the remainder of 2010.

Significant Industry Factors. Our industry is affected by numerous competitive, regulatory, and other significant factors. The growth of our business relies on our ability to continue to develop new products and innovative technologies, obtain regulatory clearance and compliance for our products, protect the proprietary technology of our products and our manufacturing processes, manufacture our products cost-effectively, respond to competitive pressures specific to each of our geographic markets, including our ability to enforce non-compete agreements, and successfully market and distribute our products in a profitable manner. We, and the entire industry, are subject to extensive governmental regulation, primarily by the United States Food and Drug Administration (FDA). Failure to comply with regulatory requirements could have a material adverse effect on our business. Additionally, our industry is highly competitive and has recently experienced increased pricing pressures, specifically in the areas of reconstructive joint devices. We devote significant resources to assessing and analyzing competitive, regulatory, and economic risks and opportunities.

In December 2007, we received a subpoena from the United States Department of Justice (DOJ) through the United States Attorney’s Office for the District of New Jersey (USAO) requesting documents for the period January 1998 through the present related to any consulting and professional service agreements with orthopaedic surgeons in connection with hip or knee joint replacement procedures or products. This subpoena was served shortly after several of our knee and hip competitors agreed to resolutions with the DOJ after being subjects of investigations involving the same subject matter.

On September 29, 2010, our wholly-owned subsidiary, Wright Medical Technology, Inc. (WMT) entered into a 12-month Deferred Prosecution Agreement (DPA) with the USAO and a Civil Settlement Agreement (CSA) with the United States. Under the DPA, the USAO agrees not to prosecute WMT in connection with the matter if WMT satisfies its obligations during the 12 month term of the DPA. Pursuant to the CSA, WMT settled civil and administrative claims relating to the matter for a payment of $7.9 million without any admission by WMT. In conjunction with the CSA, WMT also entered into a five year Corporate Integrity Agreement (CIA) with the Office of the Inspector General of the United States Department of Health and Human Services. Pursuant to the DPA, an independent monitor will review and evaluate WMT’s compliance with its obligations under the DPA. Together, these agreements resolve the investigation commenced by the USAO in December 2007. The USAO specifically acknowledges in the DPA that it does not allege that WMT’s conduct adversely affected patient health or patient care.

We previously accrued a provision of approximately $8 million for an anticipated settlement of this investigation; therefore, we did not have a material impact to our consolidated financial position or results of operations during the three months ended September 30, 2010 related to these settlements. The DPA and CIA impose certain obligations on the Company to maintain compliance with U.S. healthcare regulatory laws. Our failure to do so could expose us to significant liability including, but not limited to, extension of the term of the DPA by up to 6 months, exclusion from federal healthcare program participation, including Medicaid and Medicare, civil and criminal fines or penalties, and additional litigation cost and expense. Our obligations under the DPA expire as of September 29, 2011 while our obligations under our CIA expire as of September 29, 2014.

In March 2010, comprehensive health care reform legislation in the form of the Patient Protection and Affordable Health Care Act and the Health Care and Education Reconciliation Act was enacted. Among other initiatives, these bills impose a 2.3% excise tax on domestic sales of medical devices after December 31, 2012.

A detailed discussion of these risks and other factors is provided in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2009, and Item 1A of Part II and elsewhere in this report.

14

Results of Operations

Comparison of three months ended September 30, 2010 to three months ended September 30, 2009

The following table sets forth, for the periods indicated, our results of operations expressed as dollar amounts (in thousands) and as percentages of net sales:

	Three Months Ended September 30,
	2010					2009
	Amount		% of Sales			Amount		% of Sales
Net sales	$	121,708		100.0	%	$	117,742		100.0	%
Cost of sales1		37,989		31.2	%		35,880		30.5	%
Gross profit		83,719		68.8	%		81,862		69.5	%
Operating expenses:
Selling, general and administrative1		64,877		53.3	%		63,703		54.1	%
Research and development1		8,779		7.2	%		8,537		7.3	%
Amortization of intangible assets		708		0.6	%		1,274		1.1	%
Restructuring charges		134		0.1	%		131		0.1	%
Total operating expenses		74,498		61.2	%		73,645		62.5	%
Operating income		9,221		7.6	%		8,217		7.0	%
Interest expense, net		1,532		1.3	%		1,435		1.2	%
Other income, net		313		0.3	%		108		0.1	%
Income before income taxes		7,376		6.1	%		6,674		5.7	%
Provision for income taxes		2,726		2.2	%		2,522		2.1	%
Net income	$	4,650		3.8	%	$	4,152		3.5	%

¹ These line items include the following amounts of non-cash, stock-based compensation expense for the periods indicated:

	Three Months Ended
	September 30,
			% of					% of
	2010		Sales			2009		Sales
Cost of sales	$	314		0.3	%	$	335		0.3	%
Selling, general and administrative		2,261		1.9	%		2,517		2.1	%
Research and development		492		0.4	%		480		0.4	%

15

The following table sets forth our net sales by product line for the periods indicated (in thousands) and the percentage of year-over-year change:

	Three Months Ended September 30,
	2010		2009		%Change
Hip products	$	39,956	$	40,055		(0.2	%)
Knee products		29,549		30,114		(1.9	%)
Extremity products		30,125		25,546		17.9	%
Biologics products		19,666		19,437		1.2	%
Other		2,412		2,590		(6.9	%)
Total net sales	$	121,708	$	117,742		3.4	%

The following graphs illustrate our product line net sales as a percentage of total net sales for the three months ended September 30, 2010 and 2009:

Product Line Sales as a Percentage of Total Net Sales

2010	2009

Net Sales. Overall, our net sales increased 3% in the third quarter of 2010 compared to the third quarter of 2009. We experienced continued growth in our extremity product line, which increased 18% over prior year, as well as growth of 1% in our biologics line, while we experienced declines of 0.2% and 2% in our hip and knee product lines, respectively. Geographically, our domestic net sales totaled $74.6 million in the third quarter of 2010 and $73.8 million in the third quarter of 2009, representing 61% and 63% of total net sales, respectively, and growth of 1% in 2010 compared to 2009. Our international net sales totaled $47.1 million in the third quarter of 2010, compared to $44.0 million in the third quarter of 2009, representing growth of 7%. This increase is primarily a result of increased sales in Japan, Latin America, and Australia.

Our hip product net sales totaled $40.0 million during the third quarter of 2010, representing a 0.2% decrease from the prior year. Our domestic hip sales decreased 9% over prior year due to both decreased unit volumes and decreased pricing. Internationally, hip sales increased 7% over prior year primarily due to increased sales in Japan and Latin America.

Our knee product net sales decreased 2% to $29.5 million in the third quarter of 2010 from $30.1 million during the same period in 2009. Domestically, knee sales decreased 5% from the prior year due to both decreased unit sales and decreased pricing. International knee sales increased due to higher levels of sales in Australia.

16

Our extremity product line net sales increased to $30.1 million in the third quarter of 2010, representing growth of 18% over the third quarter of 2009. Domestically, extremity product sales increased 13% over the third quarter of 2009, as higher levels of sales of our foot and ankle products were partially offset by declines in certain of our upper extremity products. Our international extremity sales increased 49% compared to the same period in 2009 primarily due to increased sales by our subsidiary in Australia.

Net sales of our biologics products totaled $19.7 million in the third quarter of 2010, representing growth of 1% over the third quarter of 2009. In the U.S., our biologics sales increased 2% in 2010, primarily due to sales of our PRO-STIM^™ Osteoinductive Bone Graft Substitute that was launched in September 2009. This increase was mostly offset by continued declines of our GRAFTJACKET^® tissue repair and containment membranes and ALLOMATRIX^® line of injectable tissue-based bone graft substitutes. Our international biologics sales decreased in the third quarter of 2010, as compared to the same period in 2009, primarily due to decreased sales to certain of our international stocking distributors.

Cost of Sales. Our cost of sales as a percentage of net sales increased from 30.5% in the third quarter of 2009 to 31.2% in the third quarter of 2010, due to unfavorable geographic mix, as our more profitable domestic sales decreased as a percentage of total sales, and increased levels of excess and obsolete inventory provisions, which were partially offset by favorable manufacturing expenses. Our cost of sales included 0.3 percentage points of non-cash, stock-based compensation expense in both 2010 and 2009. Our cost of sales and corresponding gross profit percentages can be expected to fluctuate in future periods depending upon changes in our product sales mix and prices, distribution channels and geographies, manufacturing yields, period expenses, levels of production volume, cost of raw materials, and currency exchange rates.

Selling, General and Administrative. Our selling, general and administrative expenses as a percentage of net sales totaled 53.3% in the third quarter of 2010, a 0.8 percentage point decrease from 54.1% in the third quarter of 2009. Selling, general and administrative expense for the third quarter of 2010 included $2.3 million of non-cash, stock based compensation expense (1.9% of net sales) and $942,000 of costs associated with U.S. government inquiries (0.8% of net sales). During the third quarter of 2009, selling, general and administrative expense included $2.5 million of non-cash, stock based compensation expense (2.1% of net sales) and $1.6 million of costs, primarily legal fees, associated with U.S. government inquiries (1.3% of net sales). The decrease in selling, general and administrative expenses as a percentage of sales during the third quarter of 2010 is primarily the result of lower levels of expenses associated with U.S. government inquiries and stock-based compensation expenses, as well as lower levels of cash incentive compensation. Additionally, increased spending on U.S. sales and marketing initiatives, such as our investment in our foot and ankle sales force, was offset by favorable expenses in Europe, primarily due to our restructuring efforts in Creteil, France.

We anticipate that our selling, general and administrative expenses will increase in absolute dollars to the extent that additional growth in net sales results in increases in sales commissions and royalty expense associated with those sales and requires us to expand our infrastructure. Further, in the near term, we anticipate that these expenses may increase as a percentage of net sales as we make strategic investments in order to grow our business, as our spending related to the global compliance requirements of our industry increases, and as we incur expenses associated with our independent monitor.

Research and Development. Our investment in research and development activities represented approximately 7.2% of net sales in the third quarter of 2010, as compared to 7.3% of net sales in the third quarter of 2009. Our research and development expenses include approximately $0.5 million (0.4% of net sales) of non-cash, stock-based compensation expense in both the third quarter of 2010 and 2009.

We anticipate that our research and development expenditures may increase as a percentage of net sales and will increase in absolute dollars as we continue to increase our investment in product development initiatives and clinical studies to support regulatory approvals and provide expanded proof of the efficacy of our products.

Amortization of Intangible Assets. Charges associated with the amortization of intangible assets in the third quarter of 2010 decreased compared to the same period in 2009 from 1.1% of net sales to 0.6% of net sales as a significant amount of our intangible assets became fully amortized at the end of 2009. Based on the intangible assets held as of September 30, 2010, we expect to recognize amortization expense of approximately $2.7 million for the full year of 2010, $2.5 million in 2011, $2.2 million in 2012, $1.9 million in 2013, and $1.7 million in 2014.

Interest Expense, Net. Interest expense, net, consists of interest expense of $1.6 million during the third quarters of both 2010 and 2009, primarily from borrowings under our Convertible Senior Notes due 2014, offset by interest

17

income of $0.1 and $0.2 million during the third quarter of 2010 and 2009, respectively, generated by our invested cash balances and investments in marketable securities. The amounts of interest income we realize in 2010 and beyond are subject to variability, dependent upon both the rate of invested returns we realize and the amount of excess cash balances on hand.

Provision for Income Taxes. We recorded tax provisions of $2.7 million and $2.5 million in the third quarter of 2010 and 2009, respectively. During the third quarter of 2010, our effective tax rate was approximately 37.0% as compared to 37.8% in the third quarter of 2009. This lower rate is primarily due to a higher portion of our stock-based expense being deductible under U.S. tax regulations, which is partially offset by the expiration of the U.S. Federal Research and Development tax credit on January 1, 2010.

Comparison of nine months ended September 30, 2010 to nine months ended September 30, 2009

The following table sets forth, for the periods indicated, our results of operations expressed as dollar amounts (in thousands) and as percentages of net sales:

	Nine Months Ended September 30,
	2010					2009
	Amount		% of Sales			Amount			% of Sales
Net sales	$	380,686		100.0	%	$	357,580			100.0	%
Cost of sales1		118,064		31.0	%		110,646			30.9	%
Gross profit		262,622		69.0	%		246,934			69.1	%
Operating expenses:
Selling, general and administrative1		209,089		54.9	%		196,133			54.9	%
Research and development1		28,398		7.5	%		26,460			7.4	%
Amortization of intangible assets		1,991		0.5	%		3,899			1.1	%
Restructuring charges		1,139		0.3	%		991			0.3	%
Total operating expenses		240,617		63.2	%		227,483			63.6	%
Operating income		22,005		5.8	%		19,451			5.4	%
Interest expense, net		4,550		1.2	%		3,974			1.1	%
Other expense (income), net		270		0.1	%		(358	)		(0.1	%)
Income before income taxes		17,185		4.5	%		15,835			4.4	%
Provision for income taxes		8,213		2.2	%		5,939			1.7	%
Net income	$	8,972		2.4	%	$	9,896			2.8	%

¹ These line items include the following amounts of non-cash, stock-based compensation expense, expressed in dollar amounts (in thousands) and as percentages of net sales, for the periods indicated:

	Nine Months Ended
	September 30,
			% of					% of
	2010		Sales			2009		Sales
Cost of sales	$	980		0.3	%	$	938		0.3	%
Selling, general and administrative		7,700		2.0	%		7,822		2.2	%
Research and development		1,500		0.4	%		1,440		0.4	%

The following table sets forth our net sales by product line for the periods indicated (in thousands) and the percentage of year-over-year change:

18

	Nine Months Ended September 30,
	2010		2009		%Change
Hip products	$	130,418	$	123,030		6.0	%
Knee products		93,742		90,727		3.3	%
Extremity products		89,738		77,116		16.4	%
Biologics products		59,296		58,672		1.1	%
Other		7,492		8,035		(6.8	%)
Total net sales	$	380,686	$	357,580		6.5	%

The following graphs illustrate our product line net sales as a percentage of total net sales for the nine months ended September 30, 2010 and 2009:

Product Line Sales as a Percentage of Total Net Sales

2010	2009

Net Sales. Net sales totaled $380.7 million during the first nine months of 2010, representing a 6% increase over the first nine months in the prior year. The increase in net sales is primarily attributable to growth over prior year in our extremity product line, as well as growth in our hip product line. Additionally, sales in 2010 included a favorable currency impact of $1.8 million. Specifically, the increase in our extremities product line can be attributed to increased domestic sales in our foot and ankle products, including sales of our DARCO^® plating systems, the continued success of our CHARLOTTE^™ Foot and Ankle system, sales of our INBONE^™ products, and sales of ORTHOLOC^™ Polyaxial Locked Plating System launched in September 2009.

In the first nine months of 2010, domestic net sales increased by 3% over the first nine months of 2009 to $228.8 million, or 60% of total net sales. International sales totaled $151.9 million, including the aforementioned favorable currency impact of $1.8 million, representing an increase of 11% over the first nine months in the prior year. This increase is attributable to growth in Europe, Japan, and Australia, as well as the favorable currency impact.

Cost of Sales. Our cost of sales as a percentage of net sales increased from 30.9% in the first nine months of 2009 to 31.0% in the first nine months of 2010. This increase is primarily attributable to unfavorable geographic mix, which was mostly offset by lower levels of provisions for excess and obsolete inventory.

Operating Expenses. As a percentage of net sales, our operating expenses were 63.2% in the first nine months of 2010 compared to 63.6% in the first nine months of 2009. This decrease is due to lower levels of amortization expense, which was partially offset by increased expenses relating to the expansion of our foot and ankle sales force,

19

investments in product development initiatives and clinical studies, and increased expenses related to the U.S. government inquiry.

Provision for Income Taxes. We recorded tax provisions of $8.2 million and $5.9 million in the first nine months of 2010 and 2009, respectively. During the first nine months of 2010, our effective tax rate was approximately 47.8% as compared to 37.5% in the first nine months of 2009. This increase is primarily attributable to an unfavorable 9 percentage point impact due to the discrete tax effect of the $7.9 million charge to record the monetary payment for the settlement of the DOJ investigation. Additionally, the U.S. Federal Research and Development tax credit expired effective January 1, 2010.

Seasonal Nature of Business

We traditionally experience lower sales volumes in the third quarter than throughout the rest of the year as many of our products are used in elective procedures, which generally decline during the summer months, typically resulting in selling, general and administrative expenses and research and development expenses as a percentage of sales that are higher during this period than throughout the rest of the year. In addition, our first quarter selling, general and administrative expenses include additional expenses that we incur in connection with the annual meeting held by the American Academy of Orthopaedic Surgeons. This meeting, which is the largest orthopaedic meeting in the world, features the presentation of scientific papers and instructional courses for orthopaedic surgeons. During this three-day event, we display our most recent and innovative products to these surgeons.

Restructuring

Toulon, France

In 2007, we announced our plans to close our facilities in Toulon, France. This announcement came after a thorough evaluation in which it was determined that we had excess manufacturing capacity and redundant distribution and administrative resources that would be best eliminated through the closure of this facility. The majority of our restructuring activities were complete by the end of 2007, with production now conducted in our existing manufacturing facility in Arlington, Tennessee, and European distribution activities being carried out from our European headquarters in Amsterdam, the Netherlands. We have estimated that total pre-tax restructuring charges will be approximately $28 million to $30 million, of which we have recognized $27.5 million through September 30, 2010. We anticipate that the remaining restructuring expenses will not have a material impact on our results of operations in the period incurred, or on our financial condition or liquidity in future periods. We began realizing the benefits from this restructuring within selling, general and administrative expenses in 2008. While we began realizing the benefits from this restructuring within cost of sales in 2009, unfavorable currency exchange rates and increased raw material and other manufacturing costs offset some of those benefits. See Note 9 to our condensed consolidated financial statements for further discussion of our restructuring charges.

Creteil, France

In October 2009, we announced our plans to close our distribution and finance support office in Creteil, France, to migrate all relevant French distribution and support functions into our European organization based out of our European headquarters in Amsterdam, the Netherlands. Direct sales in France will continue and will be serviced by independent sales agents. We estimated that total pre-tax restructuring charges would be approximately $3 million to $4 million. We have recognized a total of $2.8 million through June 30, 2010, and have completed our restructuring activities in Creteil, France. We began realizing the benefits of this restructuring within selling, general, and administrative expenses in the second quarter of 2010 and have realized an improvement in working capital. See Note 9 to our condensed consolidated financial statements for further discussion of our restructuring charges.

20

Liquidity and Capital Resources

The following table sets forth, for the periods indicated, certain liquidity measures (in thousands):

	As of		As of
	September 30,		December 31,
	2010		2009
Cash and cash equivalents	$	123,170	$	84,409
Short-term marketable securities		33,512		86,819
Long-term marketable securities		34,124		—
Working capital		394,273		421,647
Line of credit availability		100,000		100,000

During 2010, we began investing in long-term marketable securities with maturity dates ranging from 17 to 36 months, consisting of investments in government, agency, and corporate bonds. As of September 30, 2010, the weighted average maturity for these investments is 23 months.

Operating Activities. Cash provided by operating activities was $60.0 million for the first nine months of 2010, as compared to $50.1 million for the first nine months of 2009. The increase in operating cash flow is primarily attributable to favorable changes in working capital, primarily for accounts receivable. Favorability in accrued expenses is primarily timing related, which was mostly offset by unfavorable changes in inventory due to new product launches.

Investing Activities. Our capital expenditures totaled approximately $36.0 million and $26.4 million in the first nine months of 2010 and 2009, respectively. The increase is attributable to increased spending on manufacturing equipment and surgical instrumentation for recent new product launches. Our industry is capital intensive, particularly as it relates to surgical instrumentation. Historically, our capital expenditures have consisted of purchased manufacturing equipment, research and testing equipment, computer systems, office furniture and equipment, and surgical instruments. We expect to incur capital expenditures of approximately $53 million in 2010.

Financing Activities. During the first nine months of 2010, cash used in financing activities totaled $214,000 compared to the first nine months of 2009 when cash provided by financing activities totaled $90,000.

On June 30, 2010, we renewed our revolving credit facility. The revolving credit facility has availability of $100 million, which can be increased by up to an additional $50 million at our request and subject to the agreement of the lenders. We currently have no borrowings outstanding under the credit facility. Borrowings under the credit facility will bear interest at the sum of a base rate or a Eurodollar rate plus an applicable margin that ranges from 0.25% to 2.50% depending on the type of loan and our consolidated leverage ratio, with a current annual base rate of 3.25% and a Eurodollar rate of 0.46% (6 month rate). The term of the credit facility extends through June 30, 2014.

The payment of our indebtedness under the credit facility is secured by pledges of 100% of the capital stock of our U.S. subsidiaries and 65% of the capital stock of our foreign subsidiaries, and is guaranteed by our U.S. subsidiaries. The credit agreement contains customary financial and non-financial covenants. Upon the occurrence of an event of default, the lenders may declare that all principal, interest and other amounts owed are immediately due and payable and may exercise any other available right or remedy. The events of default include, but are not limited to, non-payment of amounts owed, failure to perform covenants, breach of representations and warranties, institution of insolvency proceedings, entry of certain judgments, and occurrence of a change in control.

During 2007, we issued $200 million of Convertible Senior Notes due 2014, which generated net proceeds of $193.5 million. The notes pay interest semiannually at an annual rate of 2.625%. The notes are convertible into shares of our common stock at an initial conversion rate of 30.6279 shares per $1,000 principal amount of the notes, which represents a conversion price of $32.65 per share. We will make scheduled interest payments in 2010 related to the notes totaling $5.3 million.

21

Other Liquidity Information

We have funded our cash needs since 2000 through various equity and debt issuances and through cash flow from operations. In 2007, we issued $200 million of Convertible Senior Notes due 2014, which generated net proceeds totaling $193.5 million.

Although it is difficult for us to predict our future liquidity requirements, we believe that our current cash and cash equivalents balance of $123.2 million, our marketable securities balances totaling $67.6 million, our existing available credit line of $100 million, and our expected cash flow from our 2010 operations will be sufficient for the foreseeable future to fund our working capital requirements and operations, permit anticipated capital expenditures in 2010 of approximately $53 million, and meet our contractual cash obligations in 2010.

Critical Accounting Policies and Estimates

Information on judgments related to our most critical accounting policies and estimates is discussed in Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2009. Certain of our more critical accounting estimates require the application of significant judgment by management in selecting the appropriate assumptions in determining the estimate. By their nature, these judgments are subject to an inherent degree of uncertainty. We develop these judgments based on our historical experience, terms of existing contracts, our observance of trends in the industry, information provided by our customers, and information available from other outside sources, as appropriate. Actual results may differ from these judgments under different assumptions or conditions. Different, reasonable estimates could have been used for the current period. Additionally, changes in accounting estimates are reasonably likely to occur from period to period. Both of these factors could have a material impact on the presentation of our financial condition, changes in financial condition or results of operations. All of our significant accounting policies are more fully described in Note 2 to our consolidated financial statements set forth in our Annual Report on Form 10-K for the year ended December 31, 2009. There have been no significant modifications to the policies related to our critical accounting estimates since December 31, 2009.

22

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

Foreign Currency Exchange Rate Risk

Fluctuations in the rate of exchange between the U.S. dollar and foreign currencies could adversely affect our financial results. Approximately 27% and 28% of our total net sales were denominated in foreign currencies during the three months ended September 30, 2010 and for the year ended December 31, 2009, respectively, and we expect that foreign currencies will continue to represent a similarly significant percentage of our net sales in the future. Cost of sales related to these sales are primarily denominated in U.S. dollars; however, operating costs related to these sales are largely denominated in the same respective currencies, thereby partially limiting our transaction risk exposure. For sales not denominated in U.S. dollars, an increase in the rate at which a foreign currency is exchanged for U.S. dollars will require more of the foreign currency to equal a specified amount of U.S. dollars than before the rate increase. In such cases, if we price our products in the foreign currency, we will receive less in U.S. dollars than we did before the rate increase went into effect. If we price our products in U.S. dollars and our competitors price their products in local currency, an increase in the relative strength of the U.S. dollar could result in our prices not being competitive in a market where business is transacted in the local currency.

A substantial majority of our sales denominated in foreign currencies are derived from European Union countries, which are denominated in the euro; from Japan, which are denominated in the Japanese yen; from the United Kingdom, which are denominated in the British pound; and from Canada, which are denominated in the Canadian dollar. Additionally, we have significant intercompany receivables from our foreign subsidiaries which are denominated in foreign currencies, principally the euro, the yen, the British pound, and the Canadian dollar. Our principal exchange rate risk, therefore, exists between the U.S. dollar and the euro, the U.S. dollar and the yen, the U.S. dollar and the British pound, and the U.S. dollar and the Canadian dollar. Fluctuations from the beginning to the end of any given reporting period result in the revaluation of our foreign currency-denominated intercompany receivables and payables, generating currency translation gains or losses that impact our non-operating income and expense levels in the respective period.

As discussed in Note 2 to our consolidated financial statements set forth in our Annual Report on Form 10-K for the year ended December 31, 2009, we enter into certain short-term derivative financial instruments in the form of foreign currency forward contracts. These forward contracts are designed to mitigate our exposure to currency fluctuations in our intercompany balances principally denominated in euros, Japanese yen, British pounds, and Canadian dollars. Any change in the fair value of these forward contracts as a result of a fluctuation in a currency exchange rate is expected to be offset by a change in the value of the intercompany balance. These contracts are effectively closed at the end of each reporting period.

23

ITEM 4. CONTROLS AND PROCEDURES.

Disclosure Controls and Procedures

We have established disclosure controls and procedures, as such term is defined in Rule 13a-15(e) under the Securities Exchange Act of 1934. Our disclosure controls and procedures are designed to ensure that material information relating to us, including our consolidated subsidiaries, is made known to our principal executive officer and principal financial officer by others within our organization. Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness of our disclosure controls and procedures as of September 30, 2010 to ensure that the information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act of 1934 is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act of 1934 is accumulated and communicated to our management, including our principal executive officer and principal financial officer as appropriate, to allow timely decisions regarding required disclosure. Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective as of September 30, 2010.

Changes in Internal Control Over Financial Reporting

During the three months September 30, 2010, there were no significant changes in our internal control over financial reporting that materially affected, or that are reasonably likely to materially affect, our internal control over financial reporting.

24

PART II — OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS.

Not applicable.

ITEM 1A. RISK FACTORS.

If we fail to comply with the terms of the Deferred Prosecution Agreement and Corporate Integrity Agreement we entered into in September 2010, we may be subject to criminal prosecution and/or exclusion from federal healthcare programs.

As previously reported, on September 29, 2010, our wholly-owned subsidiary, Wright Medical Technology, Inc. (WMT), entered into a 12-month Deferred Prosecution Agreement (DPA) with the United States Attorney’s Office for the District of New Jersey (USAO). WMT also entered into a five year Corporate Integrity Agreement (CIA) with the Office of the Inspector General of the United States Department of Health and Human Services (OIG-HHS). Pursuant to the DPA, an independent monitor will review and evaluate WMT’s compliance with its obligations under the DPA. The DPA and CIA impose certain obligations on the Company to maintain compliance with U.S. healthcare regulatory laws. Our failure to do so could expose us to significant liability including, but not limited to, extension of the term of the DPA by up to 6 months, exclusion from federal healthcare program participation, including Medicaid and Medicare, civil and criminal fines or penalties, and additional litigation cost and expense. Our obligations under the DPA expire as of September 29, 2011 while our obligations under our CIA expire as of September 29, 2014. Any of these consequences would have a material adverse effect on our financial position, results of operations, and cash flows.

The CIA acknowledges the existence of our corporate compliance program and provides for certain other compliance-related activities during the five-year term of the agreement. If we breach the CIA, the OIG-HHS may take further action against us, up to and including excluding us from participation in federal healthcare programs, which would have a material adverse effect on our financial condition, results of operations and cash flows.

Our recent settlement with the United States Department of Justice and OIG-HHS could lead to further governmental investigations or actions by other third parties.

As a result of the allegations of wrongdoing made by the USAO and the publicity surrounding our recent settlement with the United States Department of Justice and OIG-HHS other governmental agencies, including state authorities, could conduct investigations or institute proceedings that are not precluded by terms of that settlement. In addition, the settlement with the United States Department of Justice could increase our exposure to lawsuits by potential whistleblowers under the federal false claims acts, based on new theories or allegations arising from the allegations made by the USAO. We cannot assure that the costs of defending or resolving any such investigations or proceedings would not have a material adverse effect on our financial condition, results of operations and cash flows.

Our business could be significantly and adversely impacted if certain types of healthcare reform programs are adopted and other legislative proposals are enacted into law.

In March 2010, comprehensive health care reform legislation in the form of the Patient Protection and Affordable Health Care Act and the Health Care and Education Reconciliation Act was enacted. Among other initiatives, these bills impose a 2.3% excise tax on domestic sales of medical devices following December 31, 2012, which is estimated to contribute approximately $27 billion to healthcare reform. Various healthcare reform proposals have also emerged at the state level. Outside of the excise tax, which will impact results of operations following December 31, 2012, we cannot predict with certainty what healthcare initiatives, if any, will be implemented at the state level, or what the ultimate effect of federal health care reform or any future legislation or regulation will have on us. However, an expansion in government’s role in the U.S. healthcare industry may lower reimbursements for our products, reduce medical procedure volumes, and adversely affect our business and results of operations, possibly materially.

25

PART II — OTHER INFORMATION

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

Not applicable.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

Not applicable.

ITEM 4. [Removed and Reserved.]

ITEM 5. OTHER INFORMATION.

Not applicable.

ITEM 6. EXHIBITS.

(a) Exhibits.

The following exhibits are filed as a part of this quarterly report on Form 10-Q or are incorporated herein by reference:

26

Exhibit
No.	Description
3.1	Fourth Amended and Restated Certificate of Incorporation of Wright Medical Group, Inc., (1) as amended by Certificate of Amendment of Fourth Amended and Restated Certificate of Incorporation of Wright Medical Group, Inc. (2)
3.2	Second Amended and Restated By-laws of Wright Medical Group, Inc. (3)
4.1	Form of Common Stock certificate. (1)
4.2	Indenture, dated as of November 26, 2007, between Wright Medical Group, Inc. and The Bank of New York, as trustee (including form of 2.625% Convertible Senior Notes due 2014). (4)
4.3	Underwriting Agreement, dated as of November 19, 2007, among Wright Medical Group, Inc. and J.P. Morgan Securities Inc., Piper Jaffray & Co., and Wachovia Capital Markets, LLC. (4)
10.1	Credit Agreement dated as of June 30, 2010, among Wright Medical Group, Inc., as the Borrower; the domestic subsidiaries of the Borrower, as the Guarantors; the Lenders named therein; Bank of America, N.A., as Administrative Agent, Swing Line Lender and L/C Issuer; and SunTrust Bank, as Syndication Agent. (5)
10.2	Fifth Amended and Restated 1999 Equity Incentive Plan (1999 Plan), (6) as amended by First Amendment to 1999 Plan.(7)
10.3	Amended and Restated 2009 Equity Incentive Plan (2009 Plan) (8)
10.4*	Form of Executive Stock Option Agreement pursuant to the 2009 Plan.(9)
10.5*	Form of Non-Employee Director Stock Option Agreement (one year vesting) pursuant to the 2009 Plan. (9)
10.6*	Form of Non-Employee Director Stock Option Agreement (four year vesting) pursuant to the 2009 Plan. (9)
10.7*	Form of Executive Restricted Stock Grant Agreement pursuant to the 2009 Plan. (9)
10.8*	Form of Non-Employee Director Restricted Stock Grant Agreement (one year vesting) pursuant to the 2009 Plan. (9)
10.9*	Form of Non-Employee Director Restricted Stock Grant Agreement (four year vesting) pursuant to the 2009 Plan. (9)
10.10*	Form of Executive Stock Option Agreement pursuant to the 1999 Plan. (9)
10.11*	Form of Non-Employee Director Stock Option Agreement (one year vesting) pursuant to the 1999 Plan. (9)
10.12*	Form of Non-Employee Director Stock Option Agreement (four year vesting) pursuant to the 1999 Plan. (9)
10.13*	Form of Executive Restricted Stock Grant Agreement pursuant to the 1999 Plan. (9)
10.14*	Form of Non-Employee Director Restricted Stock Grant Agreement (four year vesting) pursuant to the 1999 Plan. (10)
10.15*	Wright Medical Group, Inc. Executive Performance Incentive Plan. (11)
10.16*	Wright Medical Group, Inc. 2010 Executive Performance Incentive Plan (12)
10.17*	Form of Indemnification Agreement between Wright Medical Group, Inc. and its directors and executive officers. (13)
10.18*	Employment Agreement dated as of April 2, 2009, between Wright Medical Technology, Inc. and Gary D. Henley (13) as amended by Employment Contract Amendment dated as of August 2, 2010. (19)
10.19*	Separation Pay Agreement dated as of April 1, 2009 between Wright Medical Technology, Inc. and Lance A. Berry. (15)
10.20*	Separation Pay Agreement dated as of April 1, 2009 between Wright Medical Technology, Inc. and William L. Griffin, Jr. (16)
10.21*	Separation Pay Agreement dated as of April 1, 2009 between Wright Medical Technology, Inc. and Edward A. Steiger. (16)
10.22*	Separation Pay Agreement dated as of April 1, 2009 between Wright Medical Technology, Inc. and Frank S. Bono. (14)
10.23*	Inducement Stock Option Grant Agreement between the Registrant and Raymond C. Kolls dated May 31, 2010 (17)

27

Exhibit
No.	Description
10.24†	Supply and Development Agreement dated April 1, 2002 between Wright Medical Technology, Inc. and LifeCell Corporation, as amended January 14, 2003; February 25, 2003; May 9, 2003; July 18, 2003; March 4, 2004 and April 22, 2005. (18)
10.25	Settlement Agreement dated September 29, 2010, among the United States of America, acting through the United States Department of Justice and on behalf of the Office of Inspector General of the Department of Health and Human Services, and Wright Medical Technology, Inc. (20)
10.26	Corporate Integrity Agreement dated September 29, 2010, between Wright Medical Technology, Inc. and the Office of Inspector General of the Department of Health and Human Services (20)
10.27	Deferred Prosecution Agreement dated September 29, 2010, between Wright Medical Technology, Inc. and the United States Attorney’s Office for the District of New Jersey (20)
11	Computation of earnings per share (included in Note 7 of the Notes to Condensed Consolidated Financial Statements in “Financial Statements and Supplementary Data”).
31.1	Certification of Chief Executive Officer Pursuant to Rule 13a-14(a) Under the Securities Exchange Act of 1934.
31.2	Certification of Chief Financial Officer Pursuant to Rule 13a-14(a) Under the Securities Exchange Act of 1934.
32	Certification of Chief Executive Officer and Chief Financial Officer Pursuant to Rule 13a-14(b) Under the Securities Exchange Act of 1934 and Section 1350 of Chapter 63 of Title 18 of the United States Code.
101	The following materials from Wright Medical Group, Inc. Quarterly Report on Form 10-Q for the quarter ended September 30, 2010 formatted in XBRL (Extensible Business Reporting Language): (1) the Condensed Consolidated Balance Sheets, (2) Parenthetical Data to the Condensed Consolidated Balance Sheets, (3) the Condensed Consolidated Statements of Operations, (4) Parenthetical Data to the Condensed Consolidated Statements of Operations, (5) the Condensed Consolidated Statements of Cash Flows and (6) Notes to Condensed Consolidated Financial Statements, tagged as blocks of text.

(1)	Incorporated by reference to our Registration Statement on Form S-1 (Registration No. 333-59732), as amended.
(2)	Incorporated by reference to our Registration Statement on Form S-8 filed on May 14, 2004.
(3)	Incorporated by reference to our current report on Form 8-K filed on February 19, 2008.
(4)	Incorporated by reference to our current report on Form 8-K filed on November 26, 2007.
(5)	Incorporated by reference to our current report on Form 8-K filed on July 2, 2010.
(6)	Incorporated by reference to our definitive Proxy Statement filed on April 14, 2008.
(7)	Incorporated by reference to our quarterly report on Form 10-Q for the quarter ended September 30, 2008.
(8)	Incorporated by reference to our definitive Proxy Statement filed on April 15, 2010.
(9)	Incorporated by reference to our quarterly report on Form 10-Q for the quarter ended June 30, 2009.
(10)	Incorporated by reference to our Registration Statement on Form S-8 filed on June 18, 2008.
(11)	Incorporated by reference to our current report on Form 8-K filed on February 10, 2005.
(12)	Incorporated by reference to our current report on Form 8-K filed on March 25, 2010.
(13)	Incorporated by reference to our current report on Form 8-K filed on April 7, 2009.
(14)	Incorporated by reference to our quarterly report on Form 10-Q for the quarter ended March 31, 2009.
(15)	Incorporated by reference to our current report on Form 8-K filed on November 16, 2009.
(16)	Incorporated by reference to our quarterly report on Form 10-Q for the quarter ended March 31, 2010.

28

(17)	Incorporated by reference to our Registration Statement on Form S-8 filed June 22, 2010.
(18)	Incorporated by reference to our current report on Form 10-K filed on February 22, 2010.
(19)	Incorporated by reference to our current report on Form 8-K filed August 2, 2010.
(20)	Incorporated by reference to our current report on Form 8-K filed on September 30, 2010.
*	Denotes management contract or compensatory plan or arrangement.
†	Confidential treatment requested under 17 CFR 24b-2. The confidential portions of this exhibit have been omitted and are marked accordingly. The confidential portions have been filed separately with the Securities and Exchange Commission pursuant to the Confidential Treatment Request.

29

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: October 28, 2010

WRIGHT MEDICAL GROUP, INC.
By:	/s/ Gary D. Henley
	Gary D. Henley President and Chief Executive Officer (Principal Executive Officer)
By:	/s/ Lance A. Berry
	Lance A. Berry
	Senior Vice President and Chief Financial Officer (Principal Financial Officer and Chief Accounting Officer)

30

EXHIBIT INDEX

Exhibit
Number	DESCRIPTION
31.1	Certification of Chief Executive Officer Pursuant to Rule 13a-14(a) Under the Securities Exchange Act of 1934.
31.2	Certification of Chief Financial Officer Pursuant to Rule 13a-14(a) Under the Securities Exchange Act of 1934.
32	Certification of Chief Executive Officer and Chief Financial Officer Pursuant to Rule 13a-14(b) Under the Securities Exchange Act of 1934 and Section 1350 of Chapter 63 of Title 18 of the United States Code.
101	The following materials from Wright Medical Group, Inc. Quarterly Report on Form 10-Q for the quarter ended September 30, 2010 formatted in XBRL (Extensible Business Reporting Language): (1) the Condensed Consolidated Balance Sheets, (2) Parenthetical Data to the Condensed Consolidated Balance Sheets, (3) the Condensed Consolidated Statements of Operations, (4) Parenthetical Data to the Condensed Consolidated Statements of Operations, (5) the Condensed Consolidated Statements of Cash Flows and (6) Notes to Condensed Consolidated Financial Statements, tagged as blocks of text.

EX-31.1

EXHIBIT 31.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER
PURSUANT TO RULE 13a-14(a) UNDER
THE SECURITIES EXCHANGE ACT OF 1934

I, Gary D. Henley, certify that:

1.	I have reviewed this quarterly report on Form 10-Q for the quarter ended September 30, 2010, of Wright Medical Group, Inc. (the Company);
2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report;
4.	The Company’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Company and have:

(a)	designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including the Company’s consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)	designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)	evaluated the effectiveness of the Company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)	disclosed in this report any change in the Company’s internal control over financial reporting that occurred during the Company’s most recent fiscal quarter (the Company’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting; and

5. The Company’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company’s auditors and the audit committee of the Company’s board of directors:

(a)	all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company’s ability to record, process, summarize and report financial information; and
(b)	any fraud, whether or not material, that involves management or other employees who have a significant role in the Company’s internal control over financial reporting.

Date: October 28, 2010

/s/ Gary D. Henley  

Gary D. Henley
President and Chief Executive Officer 

EX-31.2

EXHIBIT 31.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER
PURSUANT TO RULE 13a-14(a) UNDER
THE SECURITIES EXCHANGE ACT OF 1934

I, Lance A. Berry, certify that:

1.	I have reviewed this quarterly report on Form 10-Q for the quarter ended September 30, 2010, of Wright Medical Group, Inc. (the Company);
2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report;
4.	The Company’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Company and have:

(a)	designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including the Company’s consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)	designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)	evaluated the effectiveness of the Company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)	disclosed in this report any change in the Company’s internal control over financial reporting that occurred during the Company’s most recent fiscal quarter (the Company’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting; and

5. The Company’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company’s auditors and the audit committee of the Company’s board of directors:

(a)	all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company’s ability to record, process, summarize and report financial information; and
(b)	any fraud, whether or not material, that involves management or other employees who have a significant role in the Company’s internal control over financial reporting.

Date: October 28, 2010

/s/ Lance A. Berry  

Lance A. Berry 

Senior Vice President and
Chief Financial Officer 

EX-32

EXHIBIT 32

CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND
CHIEF FINANCIAL OFFICER PURSUANT TO RULE 13a-14(b) UNDER
THE SECURITIES EXCHANGE ACT OF 1934 AND SECTION 1350 OF
CHAPTER 63 OF TITLE 18 OF THE UNITED STATES CODE

Each of the undersigned, Gary D. Henley and Lance A. Berry, certifies pursuant to Rule 13a-14(b) under the Securities Exchange Act of 1934 (the Exchange Act) and Section 1350 of Chapter 63 of Title 18 of the United States Code, that (1) this quarterly report on Form 10-Q for the quarter ended September 30, 2010, of Wright Medical Group, Inc. (the Company) fully complies with the requirements of Section 13(a) of the Exchange Act, and (2) the information contained in this report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: October 28, 2010

/s/ Gary D. Henley  

Gary D. Henley 

President and Chief Executive Officer 

/s/ Lance A. Berry  

Lance A. Berry 

Senior Vice President and
Chief Financial Officer